

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/509365

INTERNATIONAL APPLICATION NO.
PCT/EP03/03986INTERNATIONAL FILING DATE
April 14, 2003PRIORITY DATE CLAIMED
April 15, 2002TITLE OF INVENTION - FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES
SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OF TRIAZOLES

APPLICANT(S) FOR DO/EO/US:

ANGIBAUD, et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Copy of the International Published Application; Search Report Attached; Change of Assignor name; Power of Attorney or Authorization of Agent; PCT Declaration; PCT Preliminary Examination Report

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/509365		INTERNATIONAL APPLICATION NO. PCT/EP03/03986		ATTORNEY'S DOCKET NUMBER JAB-1704	
17. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.455(a)(2)) paid to USPTO..... \$760.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$670.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	10 - 20 =		x \$18.00	\$	
Independent claims	1 - 3 =		x \$78.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				+	
SUBTOTAL =				\$840.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$40.00	
TOTAL FEES ENCLOSED =				\$880.00	
				Amount to be refunded:	
				charged:	
				\$880.00	

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.


b. ☒ Please charge my Deposit Account No. 10-0750/JAB1704/MHM in the amount of \$880.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-0750/JAB1704/MHM. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Philip S. Johnson, Esq.
 Johnson & Johnson
 One Johnson & Johnson Plaza
 New Brunswick, NJ 08933-7003
 USA


 Signature
 Myra H. McCormack
 Reg. No. 36,602
 Attorney for Applicants

**JANSSEN**
PHARMACEUTICA

Naamloze Vennootschap

International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20
Switzerland

June 14, 2004

Dear Sirs,

Re : International Application No. PCT/EP03/03986

Our ref : JAB 1704-PCT /KV/nh

The above mentioned patent application was filed on April 14, 2003 by Janssen Pharmaceutica N.V.

We wish to request the recording of change in the address of two of the inventors (whom are also applicants for the US only) as provided in PCT Rule 92^{bis} 1(a)(i)-(ii).

Previous address of Angibaud, Patrick René
 Argoullon, Jean Michel Jacques Raymond

Janssen Cilag S.A.
1, rue Camille Desmoulins
TSA 91003
F-92787 Issy-les-Moulineaux
Cedex 9, France

should be changed to

Janssen-Cilag
1, rue Camille Desmoulins
TSA 91003
F-92787 Issy-les-Moulineaux
Cedex 9, France

Yours sincerely,

Karen Vermuyten
GA4736

cc. European Patent Office, Munich

DOCKET NO. JAB-1704

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ANGIBAUD et al

For : FARNESYL TRANSFERASE INHIBITING TRICYCLIC
QUINAZOLINE DERIVATIVES, SUSBTITUTED WITH CARBON-
LINKED IMIDAZOLES OR TRIAZOLES

Express Mail Certificate

"Express Mail" mailing number: EV 313408012 US

Date of Deposit: September 24, 2004

I hereby certify that this complete application, including specification pages, claims, informal drawings, Declaration and Power of Attorney, and Assignment, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Margaret Turner

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)